Association between transforming growth factor-β and hypertension

American Journal of Hypertension

Volumn 16, Issue 7, 2003, Pages 604-611

  Lijnen, Paul J ^a,b   Petrov, Victor V ^a   Fagard, Robert H ^a  

^a KU LEUVEN DEPARTMENT OF REHABILITATION SCIENCES   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Angiotensin II blockade; Blood pressure; Humans; Polymorphism; Rats; Transforming growth factor 1

Indexed keywords

MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA;

BLOOD PRESSURE; CONCENTRATION RESPONSE; DISEASE ASSOCIATION; DNA POLYMORPHISM; ENZYME INHIBITION; HEART INFARCTION; HEART LEFT VENTRICLE; HUMAN; HYPERTENSION; MICROALBUMINURIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REDUCTION; REVIEW; SHEAR STRESS;

EID: 0038235848     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(03)00847-1     Document Type: Review

References (67)

1. Villareal FJ, Dillmann WH: Cardiac hypertrophy-induced changes in mRNA levels for TGF-β, fibronectin, and collagen. Am J Physiol 1992;262:H1861-H1866.
2. Boluyt MO, O'Neill L, Meredith AL, Bing OH, Brooks WW, Conrad CH, Crow MT, Lakatta EG: Alterations in cardiac gene expression during the transition from stable hypertrophy to heart failure: Marked upregulation of gene encoding extracellular matrix components. Circ Res 1994;75:23-32.
3. Gibbons GH, Dzau VJ: The emerging concept of vascular remodeling. N Engl J Med 1994;330:1431-1438.
4. Border WA, Noble NA: Interaction of transforming growth factor-β and angiotensin II in renal fibrosis. Hypertension 1998;3:181-188.
5. Kurihara H, Yoshizumi M, Sugiyama T, Takaku F, Yanagisawa M, Masaki T, Hamaoki M, Kato H, Yazaki Y: Transforming growth factor-β stimulates the expression of endothelin mRNA by vascular endothelial cells. Biochem Biophys Res Commun 1989;159:1435-1440.
6. Dostal DE: Regulation of cardiac collagen. Angiotensin and cross-talk with local growth factors. Hypertension 2001;37:841-844.
7. 1 DNA polymorphisms, protein levels and blood pressure. Hypertension 1999;33:II-271-II-275.
8. 1 attenuates left ventricular fibrosis and improves survival without lowering blood pressure in the hypertensive TGR(mRen2)27 rat. Hypertension 2000;36:747-754.
9. Noble NA, Border WA: Angiotensin II in renal fibrosis: should TGF-β rather than blood pressure be the therapeutic agent? Sem Nephrol 1997;17:455-466.
10. Mezzano SA, Ruiz-Ortega M, Egido J: Angiotensin II and renal fibrosis. Hypertension 2001;38:635-638.
11. Yoo KH, Thornhill BA, Wolstenholme JT, Chevalier RL: Tissue-specific regulation of growth factors and clusterin by angiotensin II. Am J Hypertens 1998;11:715-722.
12. Itoh H, Mukoyama M, Pratt RE, Gibbons GH, Dzau VJ. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest 1993;91:2268-2274.
13. Gibbons GH, Pratt RE, Dzau VJ: Vascular smooth muscle cell hypertrophy vs hyperplasia. J Clin Invest 1992;90:456-461.
14. Dhaly AJ, Hoagland KM, Flasch AK, Jha S, Ledbetter SR, Roman RJ: Antihypertensive effects of chronic anti-TGF-beta antibody therapy in Dahl S rats. Am J Physiol 2002;283:R757-R767.
15. Ohta K, Kim S, Wanibuchi H, Ganten D, Iwao H: Contribution of local renin-angiotensin system to cardiac hypertrophy, phenotypic modulation and remodeling in TGR (mRen2) 27 transgenic rats. Circulation 1996;94:785-791.
16. Brooks WW, Bing OHL, Conrad CH, O'Neil L, Crow MT, Lakatta EG, Dostal DE, Baker KM, Boluyt MO' Captopril modifies gene expression in hypertrophied and failing hearts of aged spontaneously hypertensive rats. Hypertension 1997;30:1362-1368.
17. Satoh C, Fukuda N, Hu WY, Nakayama M, Kishioka H, Kammatsuse K: Role of endogenous angiotensin II in the increased expression of growth factors in vascular smooth muscle cells from spontaneously hypertensive rats. J Cardiovasc Pharmacol 2001;37:108-118.
18. Kim S, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K, Inada Y, Wada T, Ishimura Y, Chatani F, Iwao H: Role of angiotensin II in renal injury of deoxycorticosterone acetate-salt hypertensive rats. Hypertension 1994;24:195-204.
19. 1 receptor antagonism and protection against cardiovascular end-organ damage. J Hum Hypertens 1998;12:301-309.
20. 1 receptor antagonist on cardiac gene expression in hypertensive rats. Br J Pharmacol 1996;118:549-556.
21. Villareal FJ, Dillmann WH: Cardiac hypertrophy induced changes in mRNA levels for TGF-/31, fibronectin and collagen. Am J Physiol 1992;262:H1861-H1866.
22. 1 expression. Hypertension 1994;23:587-592.
23. Grimm D, Kromer EP, BtScker W, Bruckschlegel G, Holmer SR, Riegger GAJ, Schunkert H: Regulation of extracellular matrix proteins in pressure-overload cardiac hypertrophy; effects of angiotensin converting enzyme inhibition. J Hypertens 1998;16:1345-1355.
24. Deten A, Hölzl A, Leicht M. Barth W, Zimmer HG: Changes in extracellular matrix and in transforming growth factor beta isoforms after coronary artery ligation in rats. J Mol Cell Cardiol 2001;33:1191-1207.
25. Kuwahara F, Kai H, Tokuda K, Kai M, Takeshita A, Egashira K. Imaizumi T: Transforming growth factor-β function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 2002;106:130-135.
26. Hanatani A, Yoshiyama M, Kim S, Omura T, Toda I, Akioka K, Teragaki M, Takeuchi K, Iwao H, Takeda T: Inhibition by angiotensin II type 1 receptor antagonist of cardiac phenotypic modulation after myocardial infarction. J Mol Cell Cardiol 1995;27:1905-1914.
27. 1 receptor blockade and implications for early remodeling. Cardiovasc Res 2002;54:559-567.
28. 1. J Mol Cell Cardiol 2001;33:969-981.
29. Sun Y, Zhang JQ, Zhang J, Ramires FJ: Angiotensin II, transforming growth factor-beta-1 and repair in the infarcted heart. J Mol Cell Cardiol 1998;30:1559-1569.
30. Qian SW, Kondaiah P, Casscells W, Roberts AB, Sporn MB: A second messenger RNA species of transforming growth factor-beta-1 in infarcted rat heart. Cell Regulation 1991;2:241-249.
31. Casscells W, Bazoberry F, Spelt E: Transforming growth factorbeta-1 in normal heart and in myocardial infarction. Ann NY Acad Sci 1990;593:148-160.
32. Thompson NL, Bazoberry F, Speir EH: Transforming growth factor-beta-1 in acute myocardial infarction in rats. Growth Factors 1988;1:91-99.
33. Ohta K, Kim S, Iwao H: Role of angiotensin-converting enzyme, adrenergic receptors and blood pressure in cardiac gene expression of spontaneously hypertensive rats during development. Hypertension 1996;28:627-634.
34. Chen J, Gu Y, Lin F, Yang H, Zhu W, Ma J, Lin S: Endothelin receptor antagonist combined with a calcium channel blocker attenuates renal injury in spontaneous hypertensive rats with diabetes. Chin Med J 2002;115:972-978.
35. Teng J, Fukuda N, Suzuki R, Takagi H, Ikeda Y, Tahira Y, Kanmatsuse K: Inhibitory effect of a novel angiotensin II type 1 receptor antagonist RNH-6270 on growth of vascular smooth muscle cells from spontaneously hypertensive rats: Different anti-proliferative effect to angiotensin-converting enzyme inhibitor. J Cardiovasc Pharmacol 2002;39:161-171.
36. Porreca E, Di Febbo C, Mincione G, Reale M, Baccante G, Guglielmi MD, Cuccurullo F, Colletta G: Increased transforming growth factor-β production and gene expression by peripheral blood monocytes of hypertensive patients. Hypertension 1997;30:134-139.
37. 1 hyperexpression in African-American hypertensives: a novel mediator of hypertension and/or target organ damage. PNAS 2000;97:3479-3484.
38. 1 levels in hypertensive patients: Association with body mass index. Am J Hypertens 2002;15:759-765.
39. 1 in essential hypertension. Am J Hypertens 2002;15:207-211.
40. 1 is severely depressed in advanced atherosclerosis. Nature Med 1995;1:74-79.
41. 1. Hum Mol Gen 1999;8:93-97.
42. Grainger DJ, Metcalfe JC: Tamoxifen-teaching an old drug new tricks ? Nature Med 1996;2:381-385.
43. Laviades C, Varo N, Diez J: Transforming growth factor-β in hypertensives with cardiorenal damage. Hypertension 2000;36:517-522.
44. 1 and progression of hypertensive renal disease. J Hum Hypertens 2002;16:641-645.
45. Creemers EEJM, Cleutjens JPM, Stairs JFM, Daenen MJAP: Matrix metalloproteinase inhibition after myocardial infarction. A new approach to prevent heart failure? Circ Res 2001;89:201-210.
46. Spinale FG: Matrix metalloproteinases. Regulation and dysregulation in the failing heart. Circ Res 2002;90:520-530.
47. Mauviel A: Cytokine regulation of metalloproteinase gene expression. J Cell Biochem 1993;53:288-295.
48. Galis ZS, Khatri JJ: Matrix metalloproteinases in vascular remodeling and atherogenesis. The Good, the Bad and the Ugly. Circ Res 2002;90:251-262.
49. Petrov VV, Fagard RH, Lijnen PJ: Stimulation of collagen production by transforming growth factor-beta 1 during differentiation of cardiac fibroblasts to myofibroblasts. Hypertension 2002;39:258-263.
50. Narayanan AS, Page RC, Swanson J: Collagen synthesis by human fibroblasts: regulation by transforming growth factor-beta in the presence of other inflammatory mediators. Biochem J 1989;260:463-469.
51. Esmatjes E, Flores L, Inigo P, Lario S, Ruilope LM, Campistol JM: Effect of losartan on TGF-beta-1 and urinary albumin excretion in patients with type 2 diabetes mellitus and microalbuminuria. Nephrol Dial Transplant 2001;16:90-93.
52. Sharma K, Eltayeb BO, McGowan TA, Dunn SR, Alzahabi B, Rohde R, Ziyadeh FN, Lewis EJ: Captopril-induced reduction of serum levels of transforming growth factor-beta-1 correlates with long-term renoprotection in insulin-dependent diabetic patients. Am J Kidney Dis 1999;34:818-823.
53. 1 in humans. Am J Kidney Dis 2000;36:894-902.
54. Inigo P, Campistol JN, Lario S, Piera C, Campos B, Bescos M, Oppenheimer F, Rivera F: Effects of losartan and amlodipine on intrarenal hemodynamics and TGF-beta-1 plasma levels in a cross-over trial in renal transplant recipients. J Am Soc Nephrol 2001;12:822-827.
55. Agarwal R, Siva S, Dunn SR, Sharma K: Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels. Am J Kidney Dis 2002:39:486-492.
56. Houlihan CA, Akdeniz A, Tsalamandris C, Cooper ME, Jemms G, Gillbert RE: Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes and elevated albumin excretion rate: Effects of angiotensin receptor blockade and sodium restriction. Diabetes Care 2002;25:1072-1077.
57. Cambien F, Ricard S, Troesch A, Mallet C, Generenaz L, Evans A, Arveiler D, Luc G, Ruidavets JB, Poker O: Polymorphism of the transforming growth factor-beta-1 gene in relation to myocardial infarction and blood pressure: The Etude Cas-Temoin de l'Infarctur du Myocarde (ECTIM) Study. Hypertension 1996;28:881-887.
58. El-Gamel A, Awad M, Sim E, Hasleton P, Yonan N, Egan J, Deiraniya A, Hutchinson IV: Transforming growth factor-beta-1 and long allograft fibrosis. Eur J Cardiothorac Sur 1998;13:424-430.
59. 1 gene-race interactions for resting and exercise blood pressure in the HERITAGE Family Study. J Appl Physiol 2001;9:1808-1813.
60. Yamada Y, Fujisawa M, Ando F, Niino N, Tanaka M, Shimokata H: Association of a polymorphism of the transforming growth factor-beta-1 gene with blood pressure in Japanese individuals. J Hum Genet 2002;47:243-248.
61. 1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation 2000;101:2783-2787.
62. Frossard PM, Gupta A, Pravica V, Perrey C, Hutchinson IV, Lukic ML: A study of five human cytokine genes in human essential hypertension. Mol Immunol 2002;38:969-976.
63. Freedman BI, Yu H, Spray BJ, Rich SS, Rothschild CB, Bowden DW: Genetic linkage analysis of growth factor loci and end-stage renal disease in African-Americans. Kidney Int 1997;51:819-825.
64. Biggart S, Chin D, Fauchon M, Cardew G, du Fou L, Harker N, Quinn E, Keller C, Vincent R, Mayne L: Association of genetic polymorphisms in the ACE, ApoE and TGF-beta genes with early onset ischemic heart disease. Clin Cardiol 1998;21:831-836.
65. Syrris P, Carter ND, Metcalfe JC, Kemp PR, Grainger DJ, Kaski JC, Crossman DC, Francis SE, Gunn J, Jeffery S, Heathcote K: Transforming growth factor-beta-1 gene polymorphisms and coronary artery disease. Clin Sci 1998;95:659-667.
66. Roberts AB, Vodovotz Y, Roche NS, Sporn MB, Nathan CF: Role of nitric oxide in antagonistic effects of transforming growth factor-β and interleukin-1β on the beating rate of cultured cardiac myocytes. Mol Endocrinol 1992;6:1921-1930.
67. 1. Hypertension 2000;36:319-324.